As shown in Figures 10A–R, a lower IC50 of cisplatin (p = 0.0092), doxorubicin (p = 0.0025), gemcitabine (p = 3.1e-11), and mitomycin C (p = 1.4e-10) was present in the high EFNA3 expression group compared with the low expression group, indicating that HCC patients with high EFNA3 expression appeared to be more susceptible to these drugs. This evidence concerns the gene EFNA3 and hepatocellular carcinoma.